Abstract
Intestinal microecology plays an important role in the development and progression of hematological malignancies. However, characteristics of gut microbiota in diffuse large B cell lymphoma (DLBCL) have not been reported. The microbiota composition of fecal samples from 25 untreated DLBCL patients and 26 healthy volunteers was examined by 16S rRNA gene sequencing. On α-diversity analysis, there was no significant difference in species diversity and abundance between the two groups. However, a significant difference was observed on β-diversity analysis. The intestinal microbiota in patients with DLBCL showed a continuous evolutionary relationship, which progressed from phylum, proteobacteria, to genus, Escherichia-Shigella. Their abundance was significantly higher than that of the control group. At the genus level, Allisonella, lachnospira, and Roseburia were more abundant in patients with DLBCL than in the control group. Functional prediction by PICRUSt indicated that thiamine metabolism and phenylalanine, tyrosine, and tryptophan biosynthesis were significantly lower in the DLBCL group than in the control group. In conclusion, our results clearly demonstrate that the gut microbiota was changed significantly in DLBCL. The study highlights fundamental differences in the microbial diversity and composition of patients with DLBCL and paves the way for future prospective studies and microbiome-directed interventional trials to improve patient outcomes.
Highlights
Intestinal microecology plays an important role in the occurrence and development of many hematological malignancies (Christopher et al, 2019; Lee et al, 2019; Pianko et al, 2019)
Diffuse large B cell lymphoma (DLBCL) is the most common type of adult non-Hodgkin’s lymphoma (NHL), and >60% of all adult NHLs were diagnosed as diffuse large B cell lymphoma (DLBCL) in China (Abid et al, 2005)
These 25 DLBCL patients were grouped into GCB (14 cases, 58.3%) or ABC (10 cases, 41.7%) types according to pathological subtypes
Summary
Intestinal microecology plays an important role in the occurrence and development of many hematological malignancies (Christopher et al, 2019; Lee et al, 2019; Pianko et al, 2019). Gene mutations and aberrant immune responses contribute to the occurrence and development of hematological malignancies. The treatment remission rate has been increased, one-third of patients still do not benefit from the current treatment strategy (Roschewski et al, 2014). This is because the pathogenesis of DLBCL is not fully understood and the treatment is limited.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
